title: Effect of growth hormone and oxandrolone treatment on glucose metabolism in Turner syndrome. A longitudinal study.
abstract: In 18 girls with Turner syndrome, glucose tolerance was studied before treatment and after 6 and 24 months of growth-promoting treatment with recombinant human growth hormone (24 IU/m(2)/week; 8 mg/m(2)/week) and oxandrolone (0.06 mg/kg/day), as well as after termination of the treatment. One girl developed an overt non-ketotic diabetes mellitus 50 months after termination of treatment. The results of the remaining 17 girls in whom the effect of treatment on glucose metabolism was reversible are presented as a group. Their median age at the beginning of the treatment was 10.4 years (range 6.9-15.9), and 15.0 years (range 12.1-19.9) at the final assessment. There was a moderate, but not significant rise in fasting glucose throughout the course of the longitudinal study. At oral glucose tolerance testing (oGTT), the area under the curve for glucose rose significantly (p = 0.013) during the period of treatment and returned to the basic value thereafter. Fasting insulin and especially the integrated insulin values (AUCi; area under the curve for insulin) during oGTT increased continuously during treatment, declined after termination of treatment but were still significantly (p = 0.04) higher than before treatment. Considering the fact that in untreated girls with Turner syndrome the fasting insulin and the AUCi increase with age, one can conclude that the insulinaemia returned to age-specific norm after termination of treatment. Thus the effect of a combined growth hormone and oxandrolone growth-promoting treatment on glucose metabolism was fully reversible in these 17 girls with Turner syndrome.
authors.affiliation: Division of Paediatric Endocrinology, University Children's Hospital, Berne, Switzerland.
authors.forename: E E
authors.initials: EE
authors.lastname: Joss
authors.forename: R P
authors.initials: RP
authors.lastname: Zurbrügg
authors.forename: O
authors.initials: O
authors.lastname: Tönz
authors.forename: P E
authors.initials: PE
authors.lastname: Mullis
mesh_terms: D000293:Adolescent; D000328:Adult; D045930:Anabolic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D001786:Blood Glucose / Q000378:metabolism*; D002648:Child; D003920:Diabetes Mellitus / Q000097:blood / Q000209:etiology; D004359:Drug Therapy, Combination; D005260:Female; D005951:Glucose Tolerance Test; D019382:Human Growth Hormone / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D007328:Insulin / Q000097:blood / Q000378:metabolism; D000078790:Insulin Secretion; D010074:Oxandrolone / Q000008:administration & dosage / Q000009:adverse effects*; D012449:Safety; D014424:Turner Syndrome / Q000097:blood* / Q000150:complications / Q000188:drug therapy*
chemical_list: D045930:Anabolic Agents; D001786:Blood Glucose; D007328:Insulin; D019382:Human Growth Hormone; D010074:Oxandrolone